Profile data is unavailable for this security.
About the company
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
- Revenue in USD (TTM)70.32m
- Net income in USD-6.68m
- Incorporated2017
- Employees31.00
- LocationEton Pharmaceuticals Inc21925 W Field Pkwy Ste 235DEER PARK 60010-7278United StatesUSA
- Phone+1 (847) 787-7361
- Websitehttps://etonpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| X4 Pharmaceuticals Inc | 33.98m | -95.10m | 298.16m | 143.00 | -- | 1.39 | -- | 8.77 | -10.50 | -10.50 | 2.94 | 2.45 | 0.1989 | 1.75 | 25.37 | 237,615.40 | -55.66 | -55.04 | -65.82 | -63.45 | 83.24 | -- | -279.86 | -6,897.81 | 5.48 | -19.26 | 0.5525 | -- | -- | -- | 62.98 | -- | 111.28 | -- |
| AC Immune SA | 5.70m | -93.66m | 300.23m | 133.00 | -- | 3.69 | -- | 52.70 | -0.932 | -0.932 | 0.0567 | 0.8104 | 0.021 | -- | 0.3392 | 42,835.79 | -34.57 | -27.41 | -66.37 | -30.60 | -- | -- | -1,643.94 | -505.58 | -- | -- | 0.0695 | -- | 84.51 | -24.38 | 6.12 | -- | -21.11 | -- |
| Akebia Therapeutics Inc | 225.07m | -15.91m | 321.09m | 181.00 | -- | 7.72 | -- | 1.43 | -0.0761 | -0.0761 | 0.8951 | 0.1568 | 0.7879 | 2.08 | 4.57 | 1,243,486.00 | -5.57 | -38.92 | -8.55 | -61.07 | 81.89 | 71.93 | -7.07 | -76.49 | 1.80 | 0.7147 | 0.8219 | -- | -17.70 | -13.72 | -33.67 | -- | -65.40 | -- |
| Puma Biotechnology Inc | 212.00m | 36.98m | 343.67m | 172.00 | 9.20 | 2.98 | 7.14 | 1.62 | 0.7414 | 0.7414 | 4.23 | 2.29 | 1.00 | 8.06 | 4.81 | 1,232,529.00 | 17.46 | -3.25 | 32.09 | -5.70 | 76.91 | 75.67 | 17.44 | -3.18 | 1.62 | 8.84 | 0.2263 | -- | -2.19 | -3.28 | 40.23 | -- | -28.80 | -- |
| Enanta Pharmaceuticals Inc | 66.98m | -71.54m | 401.92m | 120.00 | -- | 3.17 | -- | 6.00 | -3.20 | -3.20 | 2.89 | 4.36 | 0.1975 | -- | 8.26 | 558,166.70 | -21.10 | -26.15 | -24.48 | -29.36 | -- | -- | -106.80 | -134.68 | -- | -- | 0.5181 | -- | -3.42 | -11.81 | 29.43 | -- | 54.92 | -- |
| Invivyd Inc | 50.04m | -59.86m | 439.90m | 99.00 | -- | 3.59 | -- | 8.79 | -0.4736 | -0.4736 | 0.3778 | 0.4341 | 0.3324 | -- | 5.56 | 505,444.40 | -39.76 | -- | -67.24 | -- | 93.34 | -- | -119.63 | -- | -- | -- | 0.00 | -- | -- | -- | 14.46 | -- | -- | -- |
| Aquestive Therapeutics Inc | 43.40m | -68.98m | 445.31m | 142.00 | -- | -- | -- | 10.26 | -0.7031 | -0.7031 | 0.4377 | -0.0338 | 0.3173 | 2.31 | 4.15 | 305,612.70 | -50.44 | -70.67 | -59.26 | -110.99 | 60.28 | 65.92 | -158.95 | -92.17 | 5.62 | -7.42 | 1.03 | -- | 13.80 | 1.82 | -460.83 | -- | -24.84 | -- |
| Eton Pharmaceuticals Inc | 70.32m | -6.68m | 457.78m | 31.00 | -- | 19.79 | -- | 6.51 | -0.2491 | -0.2491 | 2.63 | 0.8624 | 1.00 | 3.64 | 7.53 | 2,268,258.00 | -9.52 | -27.81 | -17.48 | -37.96 | 51.36 | 68.16 | -9.50 | -38.41 | 1.25 | 0.2114 | 0.5677 | -- | 23.29 | 109.83 | -308.44 | -- | 40.24 | -- |
| Elite Pharmaceuticals Inc | 122.89m | 13.92m | 472.78m | 68.00 | 36.07 | 7.67 | 30.39 | 3.85 | 0.0122 | 0.0122 | 0.1131 | 0.0574 | 1.20 | 3.60 | 3.94 | 1,807,255.00 | 13.55 | 13.18 | 15.31 | 16.01 | 52.66 | 47.19 | 11.33 | 13.97 | 6.34 | 2.37 | 0.0681 | 0.00 | 48.42 | 36.10 | -121.46 | -- | 135.38 | -- |
| Zevra Therapeutics Inc | 84.39m | 35.33m | 478.53m | 59.00 | 14.38 | 3.59 | 11.77 | 5.67 | 0.591 | 0.591 | 1.54 | 2.37 | 0.3656 | -- | 6.85 | 1,430,305.00 | 15.30 | -37.95 | 17.62 | -48.83 | 93.88 | -- | 41.86 | -193.51 | 8.57 | -9.57 | 0.3153 | -- | -14.02 | 12.96 | -129.13 | -- | 196.92 | -- |
| SIGA Technologies Inc | 172.25m | 74.47m | 486.24m | 46.00 | 6.56 | 2.39 | 6.48 | 2.82 | 1.03 | 1.03 | 2.40 | 2.84 | 0.8069 | 0.7425 | 23.63 | 3,744,558.00 | 34.88 | 27.72 | 39.21 | 33.36 | 76.29 | 86.06 | 43.23 | 44.28 | 7.24 | -- | 0.00 | 37.70 | -0.8561 | 38.99 | -13.01 | -- | 7.85 | -- |
| Emergent Biosolutions Inc | 788.90m | 75.90m | 568.79m | 900.00 | 8.37 | 0.9798 | 3.27 | 0.721 | 1.29 | 1.29 | 14.20 | 11.05 | 0.5369 | 1.06 | 5.83 | 876,555.60 | 5.17 | -5.03 | 5.90 | -6.47 | 54.58 | 49.01 | 9.62 | -9.76 | 3.15 | 1.85 | 0.5324 | -- | -0.5432 | -1.15 | 74.94 | -- | -25.06 | -- |
| CorMedix Inc | 214.30m | 162.50m | 578.31m | 64.00 | 3.58 | 1.54 | 3.47 | 2.70 | 2.05 | 2.05 | 2.97 | 4.78 | 0.5174 | 0.8901 | 2.44 | 3,348,495.00 | 39.23 | -42.85 | 48.05 | -49.82 | 92.61 | 91.93 | 75.83 | -327.99 | 1.73 | -- | 0.2802 | -- | -- | 173.65 | 61.31 | -- | 25.91 | -- |
Data as of Feb 13 2026. Currency figures normalised to Eton Pharmaceuticals Inc's reporting currency: US Dollar USD
42.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Opaleye Management, Inc.as of 30 Sep 2025 | 2.86m | 10.67% |
| EcoR1 Capital, LLCas of 30 Sep 2025 | 2.03m | 7.57% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 1.57m | 5.86% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.18m | 4.40% |
| Nantahala Capital Management LLCas of 31 Dec 2025 | 1.18m | 4.39% |
| Geode Capital Management LLCas of 31 Dec 2025 | 565.05k | 2.11% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 501.93k | 1.87% |
| RBC Dominion Securities, Inc. (Investment Management)as of 30 Sep 2025 | 478.80k | 1.79% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 474.19k | 1.77% |
| Westside Investment Management LLCas of 31 Dec 2025 | 470.94k | 1.76% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
